Emami share price touched 52-week lows during Thursday's trading session but the stock recovered by the end of the day. Emami touched Rs 385.5 but ended the day 1.3 percent higher at Rs 398.5.
News in Focus


Premier Energies, Waaree Energies, ONGC, Oil India shares could see higher levels in upcoming sessions as markets can recover after US President Donald Trump's announcement of withdrawing from Iran

HDFC Securities has reiterated a BUY call on Swiggy, underscoring a compelling valuation opportunity after a sharp ~37% correction over the past six months.

HDFC Securities has upgraded Eternal to a BUY rating, maintaining a target price of Rs 340, signaling a compelling upside from current levels.

Motilal Oswal Financial Services has reiterated a BUY call on Adani Ports & SEZ (APSEZ), with a target price of Rs 1,820, implying an upside potential of nearly 39% from the current market pric
Main Regional Stories

Geojit Financial Services has reiterated a BUY call on TTK Prestige Limited, positioning the stock as a compelling opportunity following a sharp valuation correction.

A cyber breach targeting FBI Director Kash Patel has exposed a tranche of personal emails, underscoring the evolving sophistication of state-linked hacking groups amid heightened geopolitical tensions.

In an increasingly fragmented and technologically driven financial ecosystem, FinAIBox has emerged as a new entrant aiming to redefine how traders and investors interact with global markets.

Rising living costs and changing financial needs have made borrowing a practical choice for many people. The real benefit, however, comes from choosing a low-interest personal loan that keeps EMIs affordable and repayment predictable.
New Delhi: Punjab National Bank (PNB) increased its fixed de
In early trading (10:02 am), Advanta India is quoting at Rs 856, up Rs 65.85, or 8.33%. It is swapping with volume of 7,271 shares.
Hyderabad: Cipla Ltd will produce the primary three-in-one cocktail anti-AIDS medicine used for children. This accompanies the USFDA clearing a combining quantity of Boehringer Ingelheim’s Viramune, GlaxoSmithKline’s Epivir (or lamivudine) and Bristol-Myers Squibb’s Zerit (or stavudine), which are anti-retrovirals or drugs that fight back AIDS.









